Format

Send to

Choose Destination
PLoS One. 2011 Feb 17;6(2):e14709. doi: 10.1371/journal.pone.0014709.

Enhanced uridine bioavailability following administration of a triacetyluridine-rich nutritional supplement.

Author information

1
University of California San Francisco, San Francisco, California, United States of America. melissa.weinberg@gmail.com

Abstract

BACKGROUND:

Uridine is a therapy for hereditary orotic aciduria and is being investigated in other disorders caused by mitochondrial dysfunction, including toxicities resulting from treatment with nucleoside reverse transcriptase inhibitors in HIV. Historically, the use of uridine as a therapeutic agent has been limited by poor bioavailability. A food supplement containing nucleosides, NucleomaxX®, has been reported to raise plasma uridine to supraphysiologic levels.

METHODOLOGY/PRINCIPAL FINDINGS:

Single- and multi-dose PK studies following NucleomaxX® were compared to single-dose PK studies of equimolar doses of pure uridine in healthy human volunteers. Product analysis documented that more than 90% of the nucleoside component of NucleomaxX® is in the form of triacetyluridine (TAU). Single and repeated dosing with NucleomaxX® resulted in peak plasma uridine concentrations 1-2 hours later of 150.9 ± 39.3 µM and 161.4 ± 31.5 µM, respectively, levels known to ameliorate mitochondrial toxicity in vitro. C(max) and AUC were four-fold higher after a single dose of NucleomaxX® than after uridine. No adverse effects of either treatment were observed.

CONCLUSIONS/SIGNIFICANCE:

NucleomaxX®, containing predominantly TAU, has significantly greater bioavailability than pure uridine in human subjects and may be useful in the management of mitochondrial toxicity.

PMID:
21379380
PMCID:
PMC3040752
DOI:
10.1371/journal.pone.0014709
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center